- Conditions
- Diabetes, Interleukins, Cytokines
- Interventions
- laparoscopic gastric bypass plus omentectomy
- Procedure
- Lead sponsor
- Legacy Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Portland, Oregon
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1681–1704
of 9,379
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Type1diabetes
- Interventions
- Insulin pump
- Device
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Guselkumab dose 1, Guselkumab dose 2, Guselkumab dose 3, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Largo, Florida • Ocala, Florida + 14 more
- Conditions
- Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
- Interventions
- Lumacaftor Plus Ivacaftor Combination, Ivacaftor, Placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 559 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 45 more
- Conditions
- Hypertrophic Cardiomyopathy
- Interventions
- EDG-7500
- Drug
- Lead sponsor
- Edgewise Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 21
- States / cities
- San Francisco, California • Stanford, California • Atlanta, Georgia + 16 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Simtuzumab, Simtuzumab placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 45 Years to 85 Years
- Enrollment
- 544 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 55 more
- Conditions
- Pancreatic Cancer
- Interventions
- erlotinib hydrochloride, gemcitabine hydrochloride, therapeutic conventional surgery
- Drug · Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2019
- U.S. locations
- 23
- States / cities
- La Jolla, California • Los Angeles, California • Orange, California + 17 more
- Conditions
- Small Cell Lung Cancer Metastatic or Locally Advanced, Neuroendocrine Cancer, Metastatic Neuroendocrine Prostate Cancer, Metastatic Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinoma, Metastatic Advanced Merkel Cell Carcinoma, Locally Advanced Large Cell Neuroendocrine Carcinoma of the Lung, Locally Advanced Extrapulmonary Neuroendocrine Carcinoma, Locally Advanced Neuroendocrine Prostate Cancer, Locally Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine, Locally Advanced Merkel Cell Carcinoma, Metastatic Large Cell Neuroendocrine Carcinoma of the Lung
- Interventions
- BL-M14D1
- Drug
- Lead sponsor
- SystImmune Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 25
- States / cities
- Huntsville, Alabama • Glendale, California • Long Beach, California + 19 more
- Conditions
- Restless Legs Syndrome (RLS), Restless Legs Syndrome
- Interventions
- ropinirole CR-RLS
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 45
- States / cities
- Jasper, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 41 more
- Conditions
- Auditory Processing Disorder
- Interventions
- Communication Counseling, Hearing Aids, Remote Microphones
- Behavioral · Device
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Temporomandibular Joint Disorders
- Interventions
- Naturopathic Medicine, Traditional Chinese Medicine
- Procedure
- Lead sponsor
- National Center for Complementary and Integrative Health (NCCIH)
- NIH
- Eligibility
- 25 Years to 55 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2004
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Parkinson's Disease
- Interventions
- Not listed
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2026
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Cincinnati, Ohio • Portland, Oregon + 1 more
- Conditions
- Malignant Glioma
- Interventions
- Biopsy Procedure, Magnetic Resonance Imaging, Radiation Therapy, Selinexor
- Procedure · Radiation · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 111
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 93 more
- Conditions
- Contraception
- Interventions
- Ovaprene
- Device
- Lead sponsor
- Daré Bioscience, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 6
- States / cities
- Sacramento, California • North Miami, Florida • Idaho Falls, Idaho + 3 more
- Conditions
- Hemophilia A, Bleeding Disorder
- Interventions
- Not listed
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 10 Years to 65 Years · Female only
- Enrollment
- 256 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Hemophilia A
- Interventions
- FVIII concentrate
- Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- Not listed
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2020
- U.S. locations
- 13
- States / cities
- Atlanta, Georgia • Indianapolis, Indiana • Lexington, Kentucky + 9 more
- Conditions
- HIV/AIDS
- Interventions
- Motivational Interviewing, Behavioral Skills Training
- Behavioral
- Lead sponsor
- University of New Mexico
- Other
- Eligibility
- 14 Years to 18 Years
- Enrollment
- 280 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Fabry Disease
- Interventions
- agalsidase alfa
- Biological
- Lead sponsor
- Shire
- Industry
- Eligibility
- Not listed
- U.S. locations
- 25
- States / cities
- Tucson, Arizona • La Jolla, California • Los Angeles, California + 21 more
- Conditions
- Neoplasms
- Interventions
- Letetresgene autoleucel, Cyclophosphamide, Fludarabine
- Drug
- Lead sponsor
- USWM, LLC (dba US WorldMeds)
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 24
- States / cities
- Duarte, California • Stanford, California • Denver, Colorado + 19 more
- Conditions
- Pain
- Interventions
- Lidocaine
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 2
- States / cities
- Portland, Oregon
- Conditions
- Esophageal Stricture
- Interventions
- GIE Medical ProTractX3 TTS DCB, Control
- Combination Product · Other
- Lead sponsor
- GIE Medical
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 198 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Irvine, California + 29 more
- Conditions
- Secondary Progressive Multiple Sclerosis
- Interventions
- BAF312, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 1,651 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2023
- U.S. locations
- 52
- States / cities
- Phoenix, Arizona • Berkeley, California • Los Angeles, California + 45 more
- Conditions
- Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma, Pancreatic Carcinoma, Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced Solid Tumors, Undifferentiated Pleomorphic Sarcoma
- Interventions
- XmAb®23104, Yervoy® (ipilimumab)
- Biological
- Lead sponsor
- Xencor, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 198 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 18
- States / cities
- San Diego, California • Aurora, Colorado • Denver, Colorado + 15 more
- Conditions
- Intermittent Exotropia
- Interventions
- Eye Patch
- Device
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 3 Years to 8 Years
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Berkeley, California + 21 more